Company intelligence / Profile preview

Lunan Pharmaceutical Group

Ownership: Private
Employees: ~5000
Development stage: Commercial

Overview

Lunan Pharmaceutical Group has multiple approved drugs in China, Japan, and the United States, including small molecules and biologics. The company has obtained 4 European and American preparation approvals, 6 CEP certificates, and 28 American DMF registrations

Therapeutic areas: PulmonologyOncologyHematologyOtherDermatologyGastroenterologyCardiovascularNephrologyInfectious Diseases
Modalities: Small molecule drugsHerbal medicineMonoclonal antibodiesBiosimilarsBispecific T-cell Engagers (BiTE)ADC (Antibody-Drug Conjugates)
Industry: Pharma

Drug pipeline

10 assets

shouhui tongbian

9 more assets in the full pipeline.

Request access →

Partnerships

Adcoris Biopharma Co., LTD. (strategic collaboration for ADC product co-development)

Beyond the preview

Go deeper on Lunan Pharmaceutical Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lunan Pharmaceutical Group.

Explore the full profile